2-chloro-4-ethynylaniline | 950601-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-4-ethynylaniline
• CAS: 950601-93-1
• 化学式: C₈H₆ClN
• 分子量: 151.595
• InChiKey: KGJRKZUOVFCSRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-4-ethynylaniline 、 生成 2-[1-(2-chloro-4-cyclopropyl-phenyl)tetrazol-5-yl]sulfanyl-N-(2-chloro-4-ethynyl-phenyl)acetamide
  参考文献：
  名称：

  Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases

  摘要：

  A series of aryl thiotetrazolylacetanilides were synthesized and found to be potent inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. The incorporation of an alkynyl fragment on the aniline provided inhibitors with excellent cellular activity and extensive SAR led to the identification of one inhibitor having good oral bioavailability in rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.012
• 作为产物：
  描述：

  2-氯-4-碘苯胺 、 乙炔 在 四(三苯基膦)钯 copper(l) iodide 、 二乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-chloro-4-ethynylaniline
  参考文献：
  名称：

  Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases

  摘要：

  A series of aryl thiotetrazolylacetanilides were synthesized and found to be potent inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. The incorporation of an alkynyl fragment on the aniline provided inhibitors with excellent cellular activity and extensive SAR led to the identification of one inhibitor having good oral bioavailability in rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.012

文献信息

• Substituted hydantoins
  申请人：Chen Shaoqing

  公开号：US20070197617A1

  公开（公告）日：2007-08-23

  The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

  本发明涉及公式化合物的方法，其制备方法以及它们的使用方法。这些化合物在治疗由MEK高活性特征的疾病中很有用。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病中很有用。
• METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
  申请人：Niu Huifeng

  公开号：US20080207563A1

  公开（公告）日：2008-08-28

  Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

  本文揭示了通过将肿瘤细胞与MEK抑制剂化合物和厄洛替尼接触，无论是顺序地还是同时地，协同抑制肿瘤细胞增殖的方法。还揭示了通过向人体逐步或同时施用厄洛替尼和MEK抑制剂化合物的方法，其中这些量在组合时对于协同抑制人体内肿瘤细胞增殖是有效的。
• 一种可回收套用的芳香胺试剂及其制备和应用
  申请人：浙江新和成股份有限公司

  公开号：CN113912551B

  公开（公告）日：2023-04-18

  本发明公开了一种可回收套用的芳香胺试剂及其制备和应用，该芳香胺试剂是利用3‑氯丙基三乙氧基硅烷作为反应的连接体，制备3‑叠氮丙基三乙氧基硅烷，通过点击化学得到取代芳香胺，将取代芳香胺通过连接体固载在介孔硅胶上得到，将该芳香胺试剂先与钠代盐反应，再与游离乙脒环合生成2‑甲基‑4‑氨基‑5‑甲酰胺甲基嘧啶，同时释放芳香胺试剂，并回收循环利用。本发明不使用高度致癌的邻氯苯胺或其它小分子苯胺化合物，杜绝了维生素B1产品中邻氯苯胺类化合物的残留。同时芳香胺试剂易回收、可循环，反应收率高。同时选用的固定化载体为介孔硅胶，价格低廉、比表面积大、表面有很多键合的硅羟基，所以适用于作载体。
• Compounds and their use for reducing uric acid levels
  申请人：Acquist LLC

  公开号：US10688095B2

  公开（公告）日：2020-06-23

  Bifunctional barbiturate-derivative compounds that increase uric acid excretion and reduce uric acid production, and monofunctional barbiturate-derivative compounds that either increase uric acid excretion or reduce uric acid production are provided. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders associated with excess uric acid, and for maintaining normal uric acid levels in blood or serum, or the whole body, are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.

  提供了可增加尿酸排泄和减少尿酸生成的双官能团巴比妥酸衍生物化合物，以及可增加尿酸排泄或减少尿酸生成的单官能团巴比妥酸衍生物化合物。还提供了使用这些化合物降低血液或血清中尿酸水平、治疗与尿酸过量有关的疾病以及维持血液或血清或全身正常尿酸水平的方法。还提供了包含双官能和单官能化合物的药物组合物。
• HYDANTOIN BASED KINASE INHIBITORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1989186A1

  公开（公告）日：2008-11-12